Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
多発性硬化症(MS)患者の新規治療適用判断方法
Document Type and Number:
Japanese Patent JP6875683
Kind Code:
B2
Abstract:
According to the present invention, the therapeutic effect of an IL-6 inhibitor on MS was found to be predictable by using as indicators the amount of plasmablasts and/or the indicator of change in immature plasmablasts (amount of immature plasmablasts or amount of follicular helper T cells) in MS patients with a large amount of plasmablasts. Furthermore, IL-6 inhibitors were found to be effective against MS in which plasmablasts occur at high levels and in which the indicator of change in immature plasmablasts is high. The present invention provides methods for selecting MS cases for which treatment with an IL-6 inhibitor is effective, and also provides an effective therapeutic method for patients with MS in which plasmablast occur at high levels and in which the indicator of change in immature plasmablasts is high.

Inventors:
Takashi Yamamura
Masakazu Nakamura
Application Number:
JP2017519390A
Publication Date:
May 26, 2021
Filing Date:
May 19, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
National Research and Development Agency National Center for Neurology and Psychiatry
Chugai Pharmaceutical Co., Ltd.
International Classes:
G01N33/48; A61K39/395; A61K45/00; A61P25/00
Foreign References:
WO2014200018A1
WO2012063876A1
Other References:
千原典夫、外1名,視神経脊髄炎(NMO)における自己抗体産生細胞,医学のあゆみ,日本,2012年,Vol.240,No.6,Page.534-535
中村雅一、外2名,多発性硬化症病態におけるプラズマブラスト,日本臨床免疫学会会誌,2015年,Vol.38,No.5,Page.403-411
中村雅一、外9名,再発寛解型多発性硬化症の病態におけるIL-6依存性プラズマブラスト,日本臨床免疫学会会誌,日本,2013年,Vol.6,No.5,Page.345
Attorney, Agent or Firm:
Masao Haruna
Hatsushi Shimizu
Hirotaka Yamaguchi
Toshi Gobe
Ryuichi Inoue
Toshimitsu Sato
Koichi Niimi
Tomohiko Kobayashi
Hideki Kodera
Masato Ozeki
Kazuya Kawamoto